Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias
Circulation Journal · 2025
DOI: 10.1253/circj.cj-24-0898 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation Journal, 2025. Verfasst von Tsuyoshi Shiga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine. Hauptthemen laut MEDLINE: Morpholines, Tachycardia, Ventricular, Product Surveillance, Postmarketing, Urea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Landiolol is a short-acting, intravenously administered β1-adrenergic receptor blocker that can rapidly control heart rate in refractory and urgent fatal arrhythmias (ventricular fibrillation [VF] and hemodynamically unstable ventricular tachyarrhythmia [VT]). This indication was approved in Japan in 2019 based on results of the J-Land II clinical trial. We conducted post-marketing surveillance (PMS) to assess the safety and effectiveness of landiolol in real-world settings in Japan. METHODS AND RESULTS: This PMS examined the safety, focusing on adverse drug reactions (ADRs) related to the safety specifications (SS), namely hypotension-decreased blood pressureSS, bradycardiaSS, and heart failureSS, and effectiveness (physician-rated) in patients treated with landiolol for the target indication. Among 253 registered patients, 13.0% experienced ADRs related to the safety specifications: bradycardiaSS(7.1%), hypotension-decreased blood pressureSS(6.7%), and heart failureSS(1.2%). Serious ADRs related to the safety specifications occurred in 6.7% of patients, including those related to bradycardiaSS(3.2%), hypotension-decreased blood pressureSS(3.2%), and heart failureSS(1.2%). The effectiveness of landiolol within 48 h after starting treatment was rated as effective (52.4%), slightly effective (27.0%), not effective (18.7%), and indeterminate (2.0%). CONCLUSIONS: The safety profile of landiolol in this PMS was similar to that observed in a prior clinical trial, and no new safety signals were identified. Landiolol is an option for treating refractory and potentially fatal VF or hemodynamically unstable VT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine.
- Section 2, PMS Office, Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd.
- Section 3, Strategy Office, Safety Management Department, Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd.
- Medical Information Section, Medical Resource Division, Department of Medical Affairs, Ono Pharmaceutical Co., Ltd.
- Section 1, Primary Medical Affairs Division, Department of Medical Affairs, Ono Pharmaceutical Co., Ltd.
Zitieren
APA
Shiga, T., Shiozaki, M., Takahashi, R., Matsumoto, R., & Fukui, M. (2025). Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias. Circulation Journal. https://doi.org/10.1253/circj.cj-24-0898
Vancouver
Shiga T, Shiozaki M, Takahashi R, Matsumoto R, Fukui M. Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias. Circulation Journal. 2025. doi:10.1253/circj.cj-24-0898
BibTeX
@article{Shiga2025,
author = {Shiga, Tsuyoshi and Shiozaki, Masato and Takahashi, Rika and Matsumoto, Ryoji and Fukui, Masato},
title = {Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias},
journal = {Circulation Journal},
year = {2025},
doi = {10.1253/circj.cj-24-0898}
}
EUVIMED